Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heparin Crisis Leads To New U.S. FDA Policy On Consulting Outside Experts

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA's new policy for retaining outside experts in emergency situations calls for the agency to consider the risks posed by the collaboration as well as requirements for conflict-of-interest screening and disclosure

You may also be interested in...



Competition To Cooperation: Indian And Chinese Firms Agree On Draft MOU For Partnerships, Investments And GMP Training

MUMBAI - Intense price competition in key developed markets and common concerns for quality products and GMP issues is set to bring India and China together to boost collaborative efforts

Competition To Cooperation: Indian And Chinese Firms Agree On Draft MOU For Partnerships, Investments And GMP Training

MUMBAI - Intense price competition in key developed markets and common concerns for quality products and GMP issues is set to bring India and China together to boost collaborative efforts

Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off

Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.

Related Content

UsernamePublicRestriction

Register

LL1130496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel